These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 882111)

  • 1. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron loading and thalassemia--experimental successes and practical realities.
    Weatherall DJ; Pippard MJ; Callender ST
    N Engl J Med; 1977 Aug; 297(8):445-6. PubMed ID: 560628
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
    O'Brien RT
    Ann N Y Acad Sci; 1974; 232(0):221-5. PubMed ID: 4528431
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P; Areekul S; Isarangkura P; Chantachum Y
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
    Olivieri NF; Berriman AM; Tyler BJ; Davis SA; Francombe WH; Liu PP
    Am J Hematol; 1992 Sep; 41(1):61-3. PubMed ID: 1503101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with desferrioxamine treatment by slow subcutaneous administration, in thalassemia].
    Barcellona R; Masseria R; Palmigiano C; Amato GM
    Minerva Pediatr; 1979 May; 31(10):805-8. PubMed ID: 470858
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 20. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.